Gene expression profiling has been used to divide diffuse large B-cell lymphoma into distinct molecular subtypes with different outcomes following immunochemotherapy. Recently, researchers have shown much interest in investigating the role of biomarkers, such as BCL2, in predicting outcome in diffuse large B-cell lymphoma, particularly in the context of these molecular subtypes.
©2011 AACR.